DK0884051T3 - Cancröse metastaseinhibitorer indeholdende uracilderivater - Google Patents

Cancröse metastaseinhibitorer indeholdende uracilderivater

Info

Publication number
DK0884051T3
DK0884051T3 DK97940448T DK97940448T DK0884051T3 DK 0884051 T3 DK0884051 T3 DK 0884051T3 DK 97940448 T DK97940448 T DK 97940448T DK 97940448 T DK97940448 T DK 97940448T DK 0884051 T3 DK0884051 T3 DK 0884051T3
Authority
DK
Denmark
Prior art keywords
unsubstituted
inhibitors containing
substituted
uracil derivatives
containing uracil
Prior art date
Application number
DK97940448T
Other languages
Danish (da)
English (en)
Inventor
Kazutaka Miyadera
Tomohiro Emura
Konstanty Wierzba
Yuji Yamada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0884051T3 publication Critical patent/DK0884051T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97940448T 1996-09-24 1997-09-22 Cancröse metastaseinhibitorer indeholdende uracilderivater DK0884051T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25130396 1996-09-24
PCT/JP1997/003355 WO1998013045A1 (fr) 1996-09-24 1997-09-22 Inhibiteurs de metastases cancereuses contenant des derives d'uracile

Publications (1)

Publication Number Publication Date
DK0884051T3 true DK0884051T3 (da) 2005-01-24

Family

ID=17220808

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97940448T DK0884051T3 (da) 1996-09-24 1997-09-22 Cancröse metastaseinhibitorer indeholdende uracilderivater

Country Status (12)

Country Link
US (1) US6255314B1 (fr)
EP (1) EP0884051B1 (fr)
JP (1) JP3088758B2 (fr)
KR (1) KR100284413B1 (fr)
AT (1) ATE284694T1 (fr)
AU (1) AU699728B2 (fr)
CA (1) CA2238331C (fr)
DE (1) DE69731940T2 (fr)
DK (1) DK0884051T3 (fr)
ES (1) ES2235249T3 (fr)
PT (1) PT884051E (fr)
WO (1) WO1998013045A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4049477B2 (ja) * 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
RU2394581C2 (ru) * 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
US7799783B2 (en) 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
ES2382673T3 (es) 2006-04-13 2012-06-12 Taiho Pharmaceutical Co., Ltd. Agente terapéutico para la enfermedad inflamatoria intestinal
JP4852605B2 (ja) 2006-06-30 2012-01-11 大鵬薬品工業株式会社 放射線治療増強剤
TWI435725B (zh) * 2007-10-11 2014-05-01 Taiho Pharmaceutical Co Ltd The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis
TWI429439B (zh) 2007-10-11 2014-03-11 Taiho Pharmaceutical Co Ltd And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient
JP2010202591A (ja) * 2009-03-04 2010-09-16 Hokkaido Univ 増殖性疾患の内用放射線治療剤
KR101928618B1 (ko) 2013-05-17 2018-12-12 다이호야쿠힌고교 가부시키가이샤 Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법
GEP20186841B (en) 2013-06-17 2018-04-10 Pharmaceutical Co Ltd Taiho Stabilized crystal of tipiracil hydrochloride, and crystallization method for same
CN105906573A (zh) * 2015-12-23 2016-08-31 嘉实（湖南）医药科技有限公司 一种替吡嘧啶中间体的制备方法
EP3526199B1 (fr) * 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3450399B2 (ja) * 1993-12-28 2003-09-22 大鵬薬品工業株式会社 血管新生阻害剤
DK0763529T3 (da) * 1995-03-29 2003-11-10 Taiho Pharmaceutical Co Ltd Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme

Also Published As

Publication number Publication date
EP0884051B1 (fr) 2004-12-15
US6255314B1 (en) 2001-07-03
ES2235249T3 (es) 2005-07-01
WO1998013045A1 (fr) 1998-04-02
DE69731940D1 (de) 2005-01-20
ATE284694T1 (de) 2005-01-15
EP0884051A1 (fr) 1998-12-16
DE69731940T2 (de) 2005-05-25
JP3088758B2 (ja) 2000-09-18
KR100284413B1 (ko) 2001-03-02
CA2238331C (fr) 2003-02-25
KR19990067441A (ko) 1999-08-16
CA2238331A1 (fr) 1998-04-02
EP0884051A4 (fr) 2001-06-13
PT884051E (pt) 2005-03-31
AU4222597A (en) 1998-04-17
AU699728B2 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
DE69731940D1 (de) Uracilderivate enthaltende krebsmetastasen inhibitoren
MX9203551A (es) Derivados de fenil amidinas utiles como inhibidores de agregacion de plaquetas.
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
ES2182852T3 (es) Derivados de prolinamida.
CY1107001T1 (el) Αζωτουχα ετεροκυκλικα παραγωγα καρβοξαμιδιου ή αλας αυτων ως αντιϊκοι παραγοντες
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
NO20004485L (no) Sykloalkenderivater, deres fremstilling og anvendelse
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2003049690A3 (fr) Inhibiteurs de l'integrase du vih
ATE277011T1 (de) Flouride von 4-substituierten piperidin-derivaten
DK1043310T3 (da) Biphenylamidinderivater
ATE272617T1 (de) Sulfonamid-derivate
DK1454903T3 (da) Thiadiazolinderivater til behandling af cancer
DK0882728T3 (da) 1-methylcarbapenemderivater
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk